Journal article
Cancer therapies in HIV cure research
TA Rasmussen, JL Anderson, F Wightman, SR Lewin
Current Opinion in HIV and AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Abstract
Purpose of review: This article provides an overview of anticancer therapies in various stages of clinical development as potential interventions to target HIV persistence. Recent findings: Epigenetic drugs developed for cancer have been investigated in vitro, ex vivo and in clinical trials as interventions aimed at reversing HIV latency and depleting the amount of virus that persists on antiretroviral therapy. Treatment with histone deacetylase inhibitors induced HIV expression in patients on antiretroviral therapy but did not reduce the frequency of infected cells. Other interventions that may accelerate the decay of latently infected cells, in the presence or absence of latency-reversing ..
View full abstractRelated Projects (5)
Grants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
This work was partly supported by funding from the American Foundation for AIDS Research, amfAR (grant 109226-58-RGRL); the National Health and Medical Research Council (NHMRC) of Australia; the National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure collaboratory (U19 AI096109); and the L.E.W. Carty Charitable Fund. S.R.L. is an NHMRC Practitioner Fellow.